Cargando…

Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study

SIMPLE SUMMARY: Patients with malignant pleural mesothelioma (MPM) often have to wait a long time before receiving a diagnosis. To contribute to the research on this neoplasm, we analyzed various samples of tumor biopsy and the relative liquid biopsies from both plasma and pleural fluid. We tested t...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Gabriele, Aretini, Paolo, Lessi, Francesca, Mazzanti, Chiara Maria, Ak, Guntulu, Metintaş, Muzaffer, Lando, Cecilia, Filiberti, Rosa Angela, Lucchi, Marco, Bonotti, Alessandra, Foddis, Rudy, Cristaudo, Alfonso, Bottari, Andrea, Apollo, Alessandro, Del Re, Marzia, Danesi, Romano, Mutti, Luciano, Gemignani, Federica, Landi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157824/
https://www.ncbi.nlm.nih.gov/pubmed/34070018
http://dx.doi.org/10.3390/cancers13102445
Descripción
Sumario:SIMPLE SUMMARY: Patients with malignant pleural mesothelioma (MPM) often have to wait a long time before receiving a diagnosis. To contribute to the research on this neoplasm, we analyzed various samples of tumor biopsy and the relative liquid biopsies from both plasma and pleural fluid. We tested the possibility of obtaining information about the tumor in a quicker and less invasive way compared to the usual solid biopsy. We performed NGS on blood and tumor samples from patients and obtained a list of somatic mutations. With the digital droplet PCR technique, we tested the respective pleural fluids and plasma for the previously found mutations. We discovered that pleural fluid is a good proxy to obtain the mutational landscape of the MPM. We also tracked tumor DNA in plasma, leading to the idea that this could be used in a clinical setting to perform follow-ups of patients and monitor drug responses. ABSTRACT: Background: Malignant pleural mesothelioma (MPM) is a fatal tumor with a poor prognosis. The recent developments of liquid biopsies could provide novel diagnostic and prognostic tools in oncology. However, there is limited information about the feasibility of this technique for MPMs. Here, we investigate whether cancer-specific DNA sequences can be detected in pleural fluids and plasma of MPM patients as free circulating tumor DNA (ctDNA). Methods: We performed whole-exome sequencing on 14 tumor biopsies from 14 patients, and we analyzed 20 patient-specific somatic mutations with digital droplet PCR (ddPCR) in pleural fluids and plasma, using them as cancer-specific tumor biomarkers. Results: Most of the selected mutations could be detected in pleural fluids (94%) and, noteworthy, in plasma (83%) with the use of ddPCR. Pleural fluids showed similar levels of somatically mutated ctDNA (median = 12.75%, average = 16.3%, standard deviation = 12.3) as those detected in solid biopsies (median = 21.95%; average = 22.21%; standard deviation = 9.57), and their paired difference was weakly statistically significant (p = 0.048). On the other hand, the paired difference between solid biopsies and ctDNA from plasma (median = 0.29%, average = 0.89%, standard deviation = 1.40) was highly statistically significant (p = 2.5 × 10(−7)), corresponding to the important drop of circulating somatically mutated DNA in the bloodstream. However, despite the tiny amount of ctDNA in plasma, varying from 5.57% down to 0.14%, the mutations were detectable at rates similar to those possible for other tumors. Conclusions: We found robust evidence that mutated DNA is spilled from MPMs, mostly into pleural fluids, proving the concept that liquid biopsies are feasible for MPM patients.